U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Ingenol Mebutate (Picato): Topical Treatment of Non-hyperkeratotic, Non-hypertrophic Actinic Keratosis in Adults [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Feb.

Cover of Ingenol Mebutate (Picato)

Ingenol Mebutate (Picato): Topical Treatment of Non-hyperkeratotic, Non-hypertrophic Actinic Keratosis in Adults [Internet].

Show details

REFERENCES

1.
Ghuznavi N, Nocera NF, Guajardo AR, Weinberg JM. Emerging medical treatments for actinic keratoses, squamous cell carcinoma and basal cell carcinoma. Clinical Investigation. 2012;2(9):909–921.
2.
Jacks S, Kudrewicz K, Carr DR. Ingenol mebutate: an emerging therapy in the treatment of actinic keratoses. Current Dermatology Reports. 2013;2(2):113–117.
3.
Berman B. New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel. Clin Cosmet Investig Dermatol [Internet]. 2012. [cited 2013 Jun 18]. pp. 111–122. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles​/PMC3430094/pdf/ccid-5-111.pdf. [PMC free article: PMC3430094] [PubMed: 22956883]
4.
CDR submission binder: Picato® (ingenol mebutate) topical gel 0.015% and 0.05% [CONFIDENTIAL manufacturer's submission]. Thornhill (ON): LEO Pharma Inc.; May, 2013.
5.
de Berker D, McGregor JM, Hughes BR. Guidelines for the management of actinic keratoses. Br J Dermatol [Internet]. 2007. [cited 2013 Jul 18]. pp. 222–230. Available from: http://www​.bad.org.uk​/Portals/_Bad/Guidelines​/Clinical%20Guidelines​/Actinic%20Keratoses.pdf. [PubMed: 17223860]
6.
Gupta AK, Paquet M. Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers. J Cutan Med Surg. 2013 May;17(3):173–179. [PubMed: 23673300]
7.
Stockfleth E. The paradigm shift in treating actinic keratosis: a comprehensive strategy. J Drugs Dermatol. 2012 Dec;11(12):1462–1467. [PubMed: 23377517]
8.
Stockfleth E, Terhorst D, Braathen L, Cribier B, Cerio R, Ferrandiz C, et al. Zurich (CH): European Dermatology Forum; Oct 20, 2010. [cited 2013 Jul 18]. Guideline on Actinic Keratoses [Internet] Available from: http://www​.euroderm.org​/images/stories/guidelines​/guideline_Management​_Actinic_Keratoses-update2011​.pdf.
9.
National Institute for Health and Care Excellence. ESNM14: Actinic keratosis: ingenol mebutate gel [Internet]. London: The Institute; Mar 19, 2013. [cited 2013 Jul 30]. (Evidence summary: new medicine). Available from: http://publications​.nice​.org.uk/esnm14-actinic-keratosis-ingenol-mebutate-gel-esnm14/overview.
10.
Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012 Mar 15;366(11):1010–1019. [PubMed: 22417254]
11.
Clinical study report PEP005-014: A multi-center, randomized, parallel group, double-blind, vehicle-controlled study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel, 0.05% in patients with actinic keratoses on non-head locations (REGION-I) [CONFIDENTIAL internal manufacturer's report]. Bowen Hills, QLD (Australia): Peplin Operations Pty Ltd; Sep 16, 2010.
12.
Clinical study report PEP005-016: A multi-center, randomized, parallel group, double-blind, vehicle-controlled study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel, 0.015% in patients with actinic keratoses on the head (face or scalp) (REGION-IIa) [CONFIDENTIAL internal manufacturer's report]. Bowen Hills, QLD (Australia): Peplin Operations Pty Ltd; Sep 8, 2010.
13.
Clinical study report PEP005-025: A multi-center, randomized, parallel-group, double-blind, vehicle controlled study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel, 0.015% in patients with actinic keratoses on the head (face or scalp) (REGION-IIb) [CONFIDENTIAL internal manufacturer's report]. Bowen Hills, QLD (Australia): Peplin Operations Pty Ltd; Sep 8, 2010.
14.
Clinical study report PEP005-028: A multi-center, randomized, parallel group, double-blind, vehicle-controlled study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel, 0.05% in patients with actinic keratoses on non-head locations (REGIONIb) [CONFIDENTIAL internal manufacturer's report]. Bowen Hills, QLD (Australia): Peplin Operations Pty Ltd; Sep 8, 2010.
15.
Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Picato (ingenol mebutate) gel. Company: Leo Pharma. Application No.: 202833. Approval Date: 1/23/2012. Rockville (MD): The Center; 2012. [cited 2013 Jun 3]. Medical review(s) [Internet] (FDA approval package). Available from: http://www​.accessdata​.fda.gov/drugsatfda_docs​/nda/2012/202833Orig1s000TOC.cfm.
16.
Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Picato (ingenol mebutate) gel. Company: Leo Pharma. Application No.: 202833. Approval Date: 1/23/2012. Rockville (MD): The Center; 2012. [cited 2013 Jun 3]. Statistical review(s) [Internet] (FDA approval package). Available from: http://www​.accessdata​.fda.gov/drugsatfda_docs​/nda/2012/202833Orig1s000TOC.cfm.
17.
Health Canada reviewer's report: Picato® (ingenol mebutate) [CONFIDENTIAL internal report]. Ottawa: Therapeutic Products Directorate, Health Canada; Jan 28, 2013.
18.
Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol. 1988 Jun;124(6):869–871. [PubMed: 3377516]
19.
Health Canada module 2.7.4: summary of clinical safety for actinic keratosis. CDR submission binder: Picato® (ingenol mebutate) topical gel 0.015% and 0.05% [CONFIDENTIAL manufacturer's submission]. Thornhill (ON): LEO Pharma Inc; Dec 13, 2011. p. 98. Figure 2, Mean composite LSR score on each observation day.
20.
Adherence and health-related quality of life in patients with actinic keratosis: executive summary and full report. London: Hamell Communications; 2012. Unpublished report prepared for LEO Pharma.
21.
Gupta AK, Paquet M, Villanueva E, Brintnell W. Interventions for actinic keratoses. Cochrane Database Syst Rev. 2012;12:CD004415. [PMC free article: PMC6599879] [PubMed: 23235610]
22.
Aldara (imiquimod) cream, 5% [product monograph]. Montreal: Valeant Canada; Feb 26, 2013.
23.
Zyclara (imiquimod) cream, 2.5% and 3.75% [product monograph]. Montreal: Valeant Canada; Feb 27, 2013.
24.
Efudex (flourouracil) topical cream [product monograph]. Montreal: Valeant Canada; Dec 15, 2004.
25.
Clinical study report PEP005-030: A 12-month, long-term follow-up study of patients with actinic keratoses on the head (face or scalp) who have completed day 57 in studies PEP005-016 or PEP005-025 (REGION IIa and IIb) [CONFIDENTIAL intenal manufacturer's report]. Bowen Hills, QLD (Australia): Peplin Operations Pty Ltd; Mar 28, 2011.
26.
Clinical study report PEP005-031: A 12-month, long-term follow-up study of patients with actinic keratosis on non-head areas (trunk and extremities) who have completed day 57 in study PEP005-020 [CONFIDENTIAL internal manufacturer's report]. Bowen Hills, QLD (Australia): Peplin Operations Pty Ltd; Mar 28, 2011.
27.
Clinical study report PEP005-032: A 12 month, long-term follow-up study of patients with actinic keratosis on non-head locations (trunk and extremities) who have completed day 57 in study PEP005-028 [CONFIDENTIAL internal manufacturer's report]. Bowen Hills, QLD (Australia): Peplin Operations Pty Ltd; Mar 28, 2011.
28.
Clinical study report PEP005-020: A multi-center, open-label study to evaluate the safety and efficacy of PEP005 (ingenol mebutate) gel, 0.05% in patients with actinic keratoses on non-head locations (trunk and extremities) [CONFIDENTIAL internal manufacturer's report]. Bowen Hills, QLD (Australia): Peplin Operations Pty Ltd; May 24, 2010.
29.
Lebwohl M, Shumack S, Gold LS, Melgaard A, Larsson T, Tyring SK. Long-term Follow-up Study of Ingenol Mebutate Gel for the Treatment of Actinic Keratoses. JAMA Dermatol. 2013 Mar 20:1–5. [PubMed: 23553119]
30.
Anderson L, Schmieder GJ, Werschler WP, Tschen EH, Ling MR, Stough DB, et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol. 2009 Jun;60(6):934–943. [PubMed: 19467365]
31.
Siller G, Gebauer K, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas J Dermatol. 2009 Feb;50(1):16–22. [PubMed: 19178487]
32.
Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001 Mar;5(2):105–110. [PubMed: 11443481]
33.
Chren MM. The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin [Internet]. Apr, 2012. [cited 2013 Jul 11]. pp. 231–236. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles​/PMC3269028/pdf/nihms345852.pdf. [PMC free article: PMC3269028] [PubMed: 22284137]
34.
Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes [Internet]. Feb 26, 2004. [cited 2013 Jul 11]. p. 12. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles​/PMC398419/pdf/1477-7525-2-12.pdf. [PMC free article: PMC398419] [PubMed: 14987333]
35.
Higaki Y, Kawamoto K, Kamo T, Horikawa N, Kawashima M, Chren MM. The Japanese version of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Dermatol. 2002 Nov;29(11):693–698. [PubMed: 12484430]
36.
Chen K, Yap LM, Marks R, Shumack S. Short-course therapy with imiquimod 5% cream for solar keratoses: a randomized controlled trial. Australas J Dermatol. 2003 Nov;44(4):250–255. [PubMed: 14616490]
37.
Gebauer K, Shumack S, Cowen PS. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial. Br J Dermatol. 2009 Oct;161(4):897–903. [PubMed: 19545297]
38.
Korman N, Moy R, Ling M, Matheson R, Smith S, McKane S, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol. 2005 Apr;141(4):467–473. [PubMed: 15837864]
39.
Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004 May;50(5):714–721. [PubMed: 15097955]
40.
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 Feb 29 -. NCT00828568, A therapeutic equivalence study of two imiquimod cream 5% treatments for patients with actinic keratosis. Nov 30, 2009. [cited 2013 Jul 29]. Available from: http://www​.clinicaltrials​.gov/ct2/show/NCT00828568.
41.
Ooi T, Barnetson RS, Zhuang L, McKane S, Lee JH, Slade HB, et al. Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. Br J Dermatol. 2006 Jan;154(1):72–78. [PubMed: 16403097]
42.
Stockfleth E, Meyer T, Benninghoff B, Salasche S, Papadopoulos L, Ulrich C, et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol. 2002 Nov;138(11):1498–1502. [PubMed: 12437457]
43.
Szeimies RM, Gerritsen MJ, Gupta G, Ortonne JP, Serresi S, Bichel J, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol. 2004 Oct;51(4):547–555. [PubMed: 15389189]
44.
Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol. 2007 Jul;157(1):133–141. [PubMed: 17501955]
45.
Jorizzo J, Dinehart S, Matheson R, Moore JK, Ling M, Fox TL, et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol. 2007 Aug;57(2):265–268. [PubMed: 17512087]
46.
Hanke CW, Beer KR, Stockfleth E, Wu J, Rosen T, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol. 2010 Apr;62(4):573–581. [PubMed: 20133012]
47.
Jorizzo JL, Markowitz O, Lebwohl MG, Bourcier M, Kulp J, Meng TC, et al. A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses. J Drugs Dermatol. 2010 Sep;9(9):1101–1108. [PubMed: 20865842]
48.
Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010 Apr;62(4):582–590. [PubMed: 20133013]
49.
Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007 Dec;157 Suppl 2:34–40. [PubMed: 18067630]
50.
Tanghetti E, Werschler P. Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. J Drugs Dermatol. 2007 Feb;6(2):144–147. [PubMed: 17373172]
Copyright © CADTH 2014.

You are permitted to make copies of this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish, or redistribute any material from this document in any form or by any means without the prior written permission of CADTH.

Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK195602
Contents

Views

  • PubReader
  • Print View
  • Cite this Page

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...